NCT07242274phase 3not yet recruiting

Phase 3 Trial of JMKX001899 Versus Docetaxel in Previously Treated Advanced or Metastatic KRAS G12C-Mutant NSCLC

Jemincare

ClinicalTrials.gov

472

Enrollment · estimated

Countries · 1 sites

2027-12

Primary completion

9 mo ago

Record updated

Commercial relevance

Trial record references molecular eligibility required.

Molecular eligibility required

Change timeline

No changes detected yet. The first refresh records a baseline snapshot; subsequent refreshes generate field-level changes.

Signals from this trial

New trial
53/100
Opportunity
New phase 3 trial NCT07242274 posted by Jemincare: "Phase 3 Trial of JMKX001899 Versus Docetaxel in Previously Treated Advanced or Metastatic KRAS G12C-Mutant NSCLC".
ClinicalTrials.gov record updated 291 days ago.

Eligibility — raw, for validation

Inclusion Criteria:

1. Age ≥ 18 years.
2. Histologically or cytologically confirmed NSCLC.
3. Failure of at least one prior line of therapy for locally advanced/metastatic disease, that included a platinum-based chemotherapy and a PD-1/PD-L1 inhibitor.
4. At least one measurable lesion as defined by RECIST version 1.1.

Exclusion Criteria:

1. Known concomitant presence of other oncogenic driver mutations or rearrangements with established targeted therapies .
2. Previous treatment with any KRAS G12C-targeted agent.
3. Prior docetaxel therapy in the locally advanced/metastatic setting.